The number of diagnosed acute heart failure (AHF) events and prevalent chronic heart failure (CHF) cases in the seven major markets that we cover is increasing annually, driven by changes in the population size and composition. Consequently, heart failure is a significant healthcare burden, related primarily to hospitalizations. The prognosis for heart failure patients after hospitalization remains bleak: the rate of recurrent hospitalization at one year approaches 70%, and the incidence of death at one year is approximately 42%. Pharmacological therapy for AHF has been unchanged for decades. No treatment has yet been shown, convincingly, to reduce morbidity and mortality in CHF patients with preserved ejection fraction. Recent efforts to develop new therapies for AHF and CHF have been largely unsuccessful. Therefore, a significant unmet need and opportunity exists for heart failure therapies that can improve symptoms and patient survival and reduce the rate of rehospitalization..
Questions Answered in This Report:
- Emerging AHF therapies will compete with AHF treatments that are well established but have little evidence-based support. Which emerging agents offer improved efficacy, stronger safety profiles, or more convenient administration than current agents and are capable of displacing generic formulations of the more established AHF agents? What impact will they have on the AHF market?
- The development of effective therapies for AHF and CHF has been plagued by numerous failures and near misses. How have these failures affected thought leaders’ opinions on the efficacy and safety of the novel drug therapies in development? What therapeutic approaches are still under development for AHF and CHF, and what do thought leaders think of these approaches?
- Emerging CHF therapies will compete with treatments that are well established and have strong evidence-based support. How do interviewed thought leaders anticipate using these novel agents in the treatment of CHF? What are the likely target populations? What impact will they have on the CHF market?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 20 country-specific interviews with cardiologists.
Epidemiology: Diagnosed prevalence of CHF cases segmented by NYHA classification; diagnosed events of AHF in the major pharmaceutical markets in 2013-2023.
Population segments in market forecast: AHF, AHF events; CHF, CHF cases segmented by NYHA functional classification (I-IV).
Emerging therapies: Phase II: 15 drugs; Phase III: 8 drugs. Coverage of 6 select preclinical and Phase I products.
Market forecast features: Using a patient-based model, we forecast drug sales for the treatment of AHF and CHF through 2023, including forecast segmentation in CHF by NYHA classification.
Lade Ayodele, M.B.B.S., M.P.H.